Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A potential game-changer for a blinding disease: The FDA has granted orphan drug designation to OCT-980, an oral treatment targeting rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). Developed by Octant Bio, the drug aims to fix misfolded rhodopsin proteins in the retina that cause progressive vision loss. A phase 1b/2 clinical trial is now underway, with the first patient dosed in September 2026.
A potential game-changer for a blinding disease
The FDA has granted orphan drug designation to OCT-980, an oral therapy developed by Octant Bio for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP) — a rare, inherited condition that causes progressive and currently untreatable vision loss. The drug works by targeting the root cause: the buildup of misfolded rhodopsin proteins in the retina that gradually destroy photoreceptor cells.
With no approved treatments currently available for RHO-adRP, the orphan drug designation is a meaningful regulatory milestone, offering Octant Bio incentives like tax credits, reduced fees, and market exclusivity to accelerate development. A phase 1b/2 clinical trial is now actively enrolling, with the first patient dosed in September 2026 across two trial sites in Oregon and Texas.
Key Takeaways
Why it matters: Retinitis pigmentosa affects roughly 1 in 4,000 people worldwide, and patients with the rhodopsin-associated dominant form have had no treatment options — making OCT-980 a closely watched candidate in the rare eye disease space.
